Wall Street Zen downgraded shares of Humacyte (NASDAQ:HUMA – Free Report) from a sell rating to a strong sell rating in a research report released on Saturday morning.
A number of other equities research analysts also recently weighed in on the company. HC Wainwright lifted their target price on Humacyte from $3.00 to $4.00 and gave the stock a “buy” rating in a report on Thursday, June 11th. TD Cowen decreased their price target on shares of Humacyte from $1.50 to $1.25 and set a “buy” rating on the stock in a research note on Wednesday, June 17th. BTIG Research reaffirmed a “buy” rating and set a $2.00 price target on shares of Humacyte in a research report on Wednesday, August 12th. Benchmark dropped their price objective on shares of Humacyte from $2.00 to $1.00 and set a “speculative buy” rating for the company in a research note on Thursday, August 13th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Humacyte in a report on Wednesday, July 8th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.11.
Check Out Our Latest Stock Analysis on Humacyte
Humacyte Price Performance
Humacyte (NASDAQ:HUMA – Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.05). The firm had revenue of $0.41 million for the quarter, compared to analyst estimates of $1.04 million. Humacyte had a negative return on equity of 983.32% and a negative net margin of 4,556.29%. Equities research analysts expect that Humacyte will post -0.38 EPS for the current year.
Institutional Trading of Humacyte
Institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC grew its holdings in shares of Humacyte by 50.3% during the 4th quarter. SG Americas Securities LLC now owns 34,075 shares of the company’s stock worth $33,000 after purchasing an additional 11,411 shares in the last quarter. Prudential Financial Inc. acquired a new position in Humacyte in the second quarter valued at about $28,000. Price T Rowe Associates Inc. MD raised its stake in Humacyte by 21.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 76,017 shares of the company’s stock valued at $73,000 after purchasing an additional 13,175 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Humacyte by 41.2% during the second quarter. The Manufacturers Life Insurance Company now owns 45,960 shares of the company’s stock worth $96,000 after purchasing an additional 13,407 shares during the period. Finally, Financial Advisors Network Inc. bought a new stake in Humacyte during the second quarter worth about $28,000. 44.71% of the stock is currently owned by institutional investors.
Humacyte Company Profile
Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.
The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.
See Also
- Five stocks we like better than Humacyte
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
